Business Description
AstraZeneca PLC
ISIN : GB0009895292
Total Employee Number:
96,100Compare
Compare
Traded in other countries / regions
AZN.UKAZN.USAAZN.SwedenAZN.ArgentinaZEG.GermanyAZN1N.MexicoA1ZN34.BrazilZEG.BulgariaAZNA.Austria IPO Date
1999-09-01Description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.72 | |||||
Debt-to-EBITDA | 1.69 | |||||
Interest Coverage | 8.18 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 3.34 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.4 | |||||
3-Year EBITDA Growth Rate | 25 | |||||
3-Year EPS without NRI Growth Rate | 32.3 | |||||
3-Year FCF Growth Rate | 2.9 | |||||
3-Year Book Growth Rate | 6.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.59 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 17.36 | |||||
9-Day RSI | 27.95 | |||||
14-Day RSI | 34 | |||||
3-1 Month Momentum % | -9.88 | |||||
6-1 Month Momentum % | -5.77 | |||||
12-1 Month Momentum % | 26.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.91 | |||||
Quick Ratio | 0.71 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 213.02 | |||||
Days Sales Outstanding | 80.46 | |||||
Days Payable | 650.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.88 | |||||
Dividend Payout Ratio | 0.48 | |||||
3-Year Dividend Growth Rate | 0.2 | |||||
Forward Dividend Yield % | 1.88 | |||||
5-Year Yield-on-Cost % | 2.09 | |||||
Shareholder Yield % | 2.46 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.68 | |||||
Operating Margin % | 23.69 | |||||
Net Margin % | 17.19 | |||||
EBITDA Margin % | 33.48 | |||||
FCF Margin % | 12.8 | |||||
OCF Margin % | 23.52 | |||||
ROE % | 22.66 | |||||
ROA % | 9.19 | |||||
ROIC % | 12.15 | |||||
3-Year ROIIC % | 126.32 | |||||
ROC (Joel Greenblatt) % | 105.55 | |||||
ROCE % | 18.13 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.99 | |||||
Forward PE Ratio | 16.66 | |||||
PE Ratio without NRI | 24.99 | |||||
Shiller PE Ratio | 47.55 | |||||
Price-to-Owner-Earnings | 24.47 | |||||
PEG Ratio | 1.11 | |||||
PS Ratio | 4.29 | |||||
PB Ratio | 5.4 | |||||
Price-to-Free-Cash-Flow | 33.53 | |||||
Price-to-Operating-Cash-Flow | 18.27 | |||||
EV-to-EBIT | 19.41 | |||||
EV-to-Forward-EBIT | 14.74 | |||||
EV-to-EBITDA | 14.07 | |||||
EV-to-Forward-EBITDA | 12.53 | |||||
EV-to-Revenue | 4.71 | |||||
EV-to-Forward-Revenue | 4.4 | |||||
EV-to-FCF | 36.79 | |||||
Price-to-GF-Value | 0.92 | |||||
Price-to-Projected-FCF | 2.29 | |||||
Price-to-Median-PS-Value | 0.92 | |||||
Price-to-Peter-Lynch-Fair-Value | 1 | |||||
Earnings Yield (Greenblatt) % | 5.15 | |||||
FCF Yield % | 3 | |||||
Forward Rate of Return (Yacktman) % | 22.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
AstraZeneca PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 51,940.633 | ||
| EPS (TTM) (€) | 5.717 | ||
| Beta | 0.5227 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.56 | ||
| Volatility % | 24.65 | ||
| 14-Day RSI | 34 | ||
| 14-Day ATR (€) | 4.340803 | ||
| 20-Day SMA (€) | 159.465 | ||
| 12-1 Month Momentum % | 26.3 | ||
| 52-Week Range (€) | 117.95 - 180.95 | ||
| Shares Outstanding (Mil) | 1,550.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AstraZeneca PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AstraZeneca PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 13:00 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 114 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-27 11:45 | In 13 days | ||
| Second quarter earnings results for 2026 | 2026-07-27 | In 12 days | ||
| Conference, J.P. Morgan European Healthcare Forum | 2026-06-18 | 153.85 (+0.00%) | ||
| Citi European Healthcare Conference, London | 2026-06-11 | 156.40 (-0.38%) | ||
| Goldman Sachs Global Healthcare Conference | 2026-06-08 | 155.80 (+0.13%) | ||
| Guidance call for 2026 | 2026-06-01 18:30 | 159.25 (-0.72%) | ||
| db Access European Champions Conference | 2026-05-27 | 161.45 (-0.86%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 09:30 | 159.75 (-0.22%) |
Show
Entries
AstraZeneca PLC Frequently Asked Questions
What is AstraZeneca PLC(HAM:ZEG)'s stock price today?
The current price of HAM:ZEG is €145.10. The 52 week high of HAM:ZEG is €180.95 and 52 week low is €117.95.
When is next earnings date of AstraZeneca PLC(HAM:ZEG)?
The next earnings date of AstraZeneca PLC(HAM:ZEG) is 2026-07-27.
Does AstraZeneca PLC(HAM:ZEG) pay dividends? If so, how much?
The Dividend Yield % of AstraZeneca PLC(HAM:ZEG) is 1.88% (As of Today), Highest Dividend Payout Ratio of AstraZeneca PLC(HAM:ZEG) was 35.15. The lowest was 0.48. And the median was 1.36. The Forward Dividend Yield % of AstraZeneca PLC(HAM:ZEG) is 1.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on AstraZeneca PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers